| Factor Information | |
|---|---|
| Data ID | 845 |
| Factor | Systemic Atrioventricular Valve (SAVV) , shunts |
| Description | While this increased survival among patients with congenital heart disease is certainly encouraging and a testament to improvements in surgical interventions and medical management, these patients frequently require repeat surgical interventions for various reasons including valvular disease. |
| Biomarker | YES |
| Classification | A3 (clinical factor - disease & symptom) |
| Association | |
|---|---|
| Application | prognosis and treatment |
| Objective | additional study in ACHD requiring SAVV intervention is needed. Such study will not only allow physicians to better advise patients but may also identify risk factors for adverse outcomes, some of which may be modifiable allowing for improved outcomes in these patients. |
| p Value | 0.045 |
| OR | 8.2 |
| Conclusion | Overall outcomes in this challenging population are good. On multivariate analysis, predischarge SAVV regurgitation grade was the only significant predictor of adverse events. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 486 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | AVSD/ccTGA/MS, MR |
| Reference | |
|---|---|
| PMID | 28520541 |
| Year | 2017 |
| Title | Outcomes and Prognostic Factors for Adult Patients With Congenital Heart Disease Undergoing Primary or Reoperative Systemic Atrioventricular Valve Surgery. |
| Sample | ||
|---|---|---|
| Population | Adults | |
| Source | retrospective cohort study | |
| Region | New York, USA | |
| Method | retrospective evaluation | |
| Race | North America | |
| Disease History | N/A | |
| Treatment History | SAVV surgery | |
| Group | Patients With CHD(Treatment) | N/A(Control) |
| Number | 43 | N/A |
| Age | 35.2 ± 12.4 years | N/A |
| Gender (Male: Female) | 20:23 | N/A |
| Marker Level | N/A | N/A |
